Compliance Watch: FDA Psychedelic Approvals Expected to Advance Despite Election Year Politics

Despite reported chaos among federal agencies and infighting within the psychedelic advocacy field, stakeholders maintain quiet confidence that FDA approvals for psychedelic candidates will proceed. While FDA reviews are expected to remain on track, broader psychedelic policy reforms may face headwinds during the election year, potentially chilling legislative progress. Advocacy specifically for ibogaine is also noted as becoming a distinct focus area.